What are the fundraising trends in the mental health market?

In our mental health market deck, you will find everything you need to understand the market

This chart, featured in our mental health market deck, shows how market revenue is split across customer segments in the mental health market

Is more or less capital going into the mental health market?

More capital is going into the mental health market, but the answer is much stronger on dollars than on breadth. Full-year capital rose from about $829M in 2024 to about $1.13B in 2025, an increase of roughly 36%, while the fresher year-to-date comparison shows about $762M in 2026 versus about $368M over the same period in 2025.

That means reported capital has more than doubled so far in 2026 compared with the same period in 2025. The mental health market is therefore not frozen, and the current-year signal is meaningfully stronger than the prior-year baseline.

The caveat is concentration. In 2025, the top 3 deals captured about 60% of total capital, and the top 10 captured about 88%. So far in 2026, the top 3 captured about 58%, and the top 10 captured about 89%. More capital is entering the mental health market, but a small number of companies still explain most of the movement.

The full-year comparison also shows selectivity. Deal count fell from 29 in 2024 to 27 in 2025 even as capital rose. That means 2025 was not a year when many more mental health companies raised money; it was a year when investors wrote bigger checks to fewer perceived winners.

The practical takeaway is that the mental health market is attracting more capital, but that capital is not evenly available. The companies absorbing the largest checks tend to have reimbursement logic, clinical infrastructure, psychiatric medication assets, FDA-cleared or clinically embedded tools, provider-network leverage, or a clear ability to expand clinical capacity.

Is mental health funding driven by more deals or larger rounds?

Mental health funding is being driven mostly by larger rounds, although the current year also shows more deals than the comparable 2025 period. The full-year comparison is clear: capital rose from about $829M in 2024 to about $1.13B in 2025 even though deal count fell from 29 to 27, so larger checks did the work.

The round-size evidence confirms that interpretation. Average round size increased from about $28.6M in 2024 to about $41.7M in 2025, but the median round slipped from $14M to $12.5M. The typical deal did not become larger in 2025; a few very large rounds pulled the average up.

The year-to-date 2026 comparison is healthier. Deals increased from 12 over the comparable 2025 period to 17 so far in 2026, while capital rose from about $368M to about $762M. Dollars grew faster than deal count, so larger rounds still matter most, but the increase is not only a one-company story.

The most important change is the median. The median round rose from $10.75M over the comparable 2025 period to $23.7M so far in 2026. That suggests the current-year rebound is reaching more than just the very top of the market, even though the top 5 rounds still captured about 71% of capital.

For more detail on the round-size distribution, concentration profile, and category-level funding mix, see the full mental health market report.

Is mental health capital moving toward later-stage or earlier-stage companies?

Mental health capital is currently moving back toward later-stage companies, even though the 2025 full-year picture looked more balanced. So far in 2026, Series B and later plus growth equity represented about 60% of capital, compared with only about 20% over the comparable 2025 period.

The current shift is driven by large follow-on and growth rounds such as Talkiatry, Grow Therapy, Big Health, Tava Health, and InStride Health. These are not experimental concept checks; they are bets on scaled care delivery, provider networks, psychiatry capacity, regulated digital treatment adoption, and payer-linked infrastructure.

The full-year 2025 stage mix needs careful interpretation. Seed plus Series A represented about 48% of 2025 capital, almost equal to late-stage capital. But several of those Series A rounds were large psychiatric medication, interventional psychiatry, or capital-intensive clinical-infrastructure rounds, so they behaved more like institutional clinical bets than ordinary early-stage software deals.

The better reading is that capital is moving toward validated risk, not simply toward a stage label. A Series A psychiatric medicine company, a Series A integrated clinic, and a Series A therapy provider have very different risk profiles. The mental health market is rewarding companies that can show clinical legitimacy, reimbursement pathways, regulated product depth, scientific specificity, or commercial scale.

This chart, featured in our mental health market deck, compares the main business model options for tele-mental health platforms

Is the mental health market maturing or still experimental?

The mental health market is maturing, but it still has an active experimental layer. The strongest evidence of maturity is that the largest checks are going to companies with clinical infrastructure, reimbursement logic, psychiatric medication assets, regulated digital treatments, or scaled provider networks.

A purely experimental market would be dominated by seed rounds, consumer apps, coaching tools, and small pilots. That is not what the funding profile shows. In 2025, Seed rounds represented about 26% of deals but only about 2% of capital; so far in 2026, Seed rounds represented about 24% of deals but only about 5% of capital.

The maturity signal is also visible in the leading companies. Grow Therapy, Talkiatry, Tava Health, InStride Health, Big Health, Salma Health, Eleos Health, MapLight, Newleos, and Syremis are tied to therapy access, psychiatry access, FDA-cleared treatment, clinical infrastructure, or psychiatric medicines rather than lightweight wellbeing products.

At the same time, the mental health market is not mature in the sense of broad, predictable, evenly distributed financing. Top-10 concentration stayed around 88% to 89% of capital in 2025 and YTD 2026. That means the market is still sorting durable winners from weaker models.

The honest interpretation is that the mental health market has moved beyond the generic digital-wellness phase. The category is maturing around clinical seriousness, provider capacity, reimbursement fit, and regulated treatment pathways, while still funding smaller experiments in AI, youth care, school-based support, and specialty therapy models.

Are new startups still entering the mental health market?

Yes, new startups are still entering the mental health market, but new-company formation is not where most current capital is going. In 2025, first financings represented about 41% of deals and about 34% of capital, up from about 28% of deals and 18% of capital in 2024.

The current-year signal is more selective. So far in 2026, first financings represented about 35% of deals but only about 22% of capital. That means new companies are still appearing, but follow-on companies are absorbing most of the dollars.

The important nuance is that first financing does not always mean small. In 2026, Salma Health raised $80M as a first financing, Ease Health raised $41M, Gilgamesh Pharma raised $60M as a post-spinout first financing, and Amani Therapeutics raised $25M. Investors will still fund new mental health companies at meaningful scale when the company attacks a difficult clinical or infrastructure bottleneck.

The strongest new entrants are not generic mental health startups. They tend to be companies focused on psychiatric drug development, serious mental illness, interventional or integrated clinics, behavioral-health infrastructure, or AI-enabled clinical workflow.

For a deeper view of which new mental health companies are entering the market and how first financings compare with follow-on capital, see the mental health market deck.

Are more investors entering the mental health market?

The evidence does not support a simple claim that more investors are entering the mental health market. Full-year 2024 had more than 130 disclosed investors across 29 deals, while full-year 2025 had about 88 disclosed investors across 27 deals. More capital came in during 2025, but it did not require a broader investor base.

The current-year comparison is somewhat more positive. So far in 2026, the mental health market had about 64 named investors across 17 deals, versus about 50 investors across 12 deals over the comparable 2025 period. That indicates more named investor participation in the current period, but much of the increase comes with more deals and larger capital deployment.

The more important change is investor quality, not raw investor count. In 2025 and 2026, the investor list includes major venture, healthcare, growth, and biotech names such as Andreessen Horowitz, General Catalyst, Goldman Sachs Alternatives, Novo Holdings, Sequoia, TCV, Menlo Ventures, F-Prime, OrbiMed, ARCH Venture Partners, Mubadala Capital, RTW, Perceptive Advisors, and Prime Movers Lab.

The best interpretation is that investor breadth is mixed, but institutional seriousness is clear. The mental health market is attracting high-quality investors into specific parts of the category: psychiatry platforms, provider networks, psychiatric medication, advanced clinics, behavioral-health infrastructure, and clinically supervised AI.

This chart, featured in our mental health market deck, illustrates yearly funding for mental health startups

Are top investors getting more or less active in the mental health market?

Top investors are getting more selectively active in the mental health market, not broadly active across every mental health model. The repeat-investor lists in 2024, 2025, and YTD 2026 show recurring participation, but the activity clusters around high-conviction areas rather than the whole category.

In 2024, recurring investors included GreyMatter, Khosla Ventures, Kinnevik, Goldman Sachs Alternatives, .406 Ventures, and Flare Capital Partners. In 2025, repeat names included F-Prime, Menlo Ventures, Goldman Sachs Alternatives, Novo Holdings, OrbiMed, Arkin Bio Capital, SR One, General Catalyst, and BoxGroup.

So far in 2026, the repeat list is shorter but high-signal. Andreessen Horowitz appeared in Talkiatry and Ease Health, .406 Ventures appeared in Big Health and InStride Health, Prime Movers Lab appeared in Gilgamesh Pharma and The Path, and General Catalyst had repeated exposure across care-delivery and youth mental health companies.

The practical reading is that top investors are not abandoning mental health. They are concentrating around companies that can control a hard constraint: psychiatrist supply, payer access, provider capacity, clinical outcomes, FDA-cleared treatment, medication pipelines, or workflow infrastructure.

Which mental health subcategories are gaining momentum?

Therapy Care Providers, Psychiatry Care Platforms, clinically embedded Clinical Mental Health Apps, and Mental Health Clinics are the subcategories gaining momentum in the mental health market. The freshest comparison is clearest: Therapy Care Providers raised about $239M so far in 2026 versus about $22M over the comparable 2025 period, while Psychiatry Care Platforms raised about $230M versus about $4M.

Therapy Care Providers are gaining momentum because the category now looks less like simple therapist matching and more like healthcare access infrastructure. Grow Therapy, Tava, InStride, and Somethings are tied to insurance, employers, payers, youth care, provider supply, or specialty treatment pathways.

Psychiatry Care Platforms are gaining momentum because psychiatry capacity is a premium bottleneck. Talkiatry’s $210M financing gave the category major weight in YTD 2026, while Blossom Health added another signal around AI-enabled psychiatry operations.

Clinical Mental Health Apps are gaining activity but not proportional capital dominance. The category produced 7 of 17 deals so far in 2026, the highest deal count of any category, but only about 16% of capital. The category is fundable when products are tied to FDA clearance, clinical workflow, provider oversight, or regulated treatment use.

Mental Health Clinics are also gaining from a weak comparable base. There were no qualifying clinic deals over the comparable 2025 period, while Salma Health and Radley Health together brought the YTD 2026 clinic total to about $83M. For more on this category rotation, see the market report covering mental health subcategory momentum.

Which mental health subcategories are losing momentum?

Addiction Treatment Services are clearly losing momentum in the mental health market. The category raised about $104M in 2024, fell to about $64M in 2025, and produced no qualifying pure-play deal in the YTD 2026 funding record.

The full-year comparison shows that addiction did not disappear in 2025, but the capital intensity weakened. Addiction Treatment Services had three deals in 2024 and four deals in 2025, yet dollars declined from $104M to $64M. Average addiction deal size fell from about $34.7M to $16M.

Psychiatric Medication Services also cooled in the current period versus an unusually strong 2025. The category raised about $233.5M over the comparable 2025 period and $771M for full-year 2025, then about $85M so far in 2026. That is a decline from a very high base, not a collapse.

Clinical Mental Health Apps are not losing momentum by deal count, but they remain capital-discounted. The category has the most YTD 2026 deals, but its capital share is far below its deal share. That means app-layer mental health companies are still forming, but most are not being treated as the largest capital sinks unless they are clinically supervised, reimbursable, FDA-cleared, or embedded in provider operations.

This chart, featured in our mental health market deck, shows why Talkspace is winning in mental health

Which regions are gaining momentum in mental health funding?

North America is the only region clearly gaining momentum in mental health funding. So far in 2026, North America accounted for all 17 qualifying deals and 100% of the approximately $762M in disclosed capital.

The full-year pattern was already North America-heavy. North America represented about 86% of 2024 deals and 97% of 2024 capital, then about 89% of 2025 deals and 87% of 2025 capital. The 2026 year-to-date record makes that dominance even more pronounced.

The reason is not simply that mental health need is larger in North America. The stronger explanation is that the largest reported venture-backed models are tied to U.S. reimbursement, insurance networks, employer distribution, provider-market fragmentation, FDA-cleared treatment pathways, and healthcare infrastructure scaling.

Companies such as Grow Therapy, Talkiatry, Tava, InStride, Big Health, Salma, Ease, and Oasys fit especially well into North American healthcare financing and delivery. The mental health market is therefore gaining momentum where the business model has the clearest payer, provider, and regulatory hooks.

Which regions are losing momentum in mental health funding?

Europe and Asia-Pacific are losing momentum in mental health funding on the freshest evidence. Europe had 3 deals and about $144M in full-year 2025, but no qualifying deal appears in the YTD 2026 record. Asia-Pacific had 2 small deals in 2024 and no qualifying deals in 2025 or YTD 2026.

Europe’s apparent 2025 strength was fragile because it was heavily driven by Draig Therapeutics. Europe’s median 2025 deal size was only about $3M, so the capital share depended far more on one large therapeutics round than on a broad European funding base.

Asia-Pacific looks weaker more consistently under the strict inclusion criteria. The region contributed about $7.9M across two 2024 deals, then disappears from the 2025 and 2026 qualifying records. That does not mean the region lacks mental health need or company formation; it means the region is not showing up in publicly disclosed, pure-play, clinically defined equity rounds above the threshold.

Latin America, the Middle East, and Africa also show no qualifying activity across the supplied 2024, 2025, and YTD 2026 figures. The mental health market’s public venture funding record remains overwhelmingly North American.

Is the mental health market becoming more global or more regionally concentrated?

The mental health market is becoming more regionally concentrated, not more global. The freshest evidence is decisive: North America accounted for 100% of qualifying deals and capital so far in 2026.

The full-year comparison adds nuance but does not change the conclusion. Europe reached about 13% of 2025 capital, but that was largely a single large therapeutics-round effect rather than a broad global expansion. In 2024, Europe and Asia-Pacific were present by deal count but small by capital.

The mental health market is globally relevant because the clinical need is global. But venture funding is not global under this strict clinical, equity-only, pure-play definition. The largest financing models depend on reimbursement, employer benefits, provider networks, FDA clearance, payer relationships, and healthcare delivery structures that are most visible in North America.

The practical rule is that international mental health company formation should not be confused with global funding depth. So far, the venture-capital center of gravity remains North American. For the broader regional breakdown, see the full market view on mental health geography.

This chart, featured in our mental health market deck, shows how teletherapy adoption has driven growth in the mental health market over time

Is mental health capital moving toward proven winners or new opportunities?

Mental health capital is moving toward proven winners in the freshest period, after a 2025 year that was more supportive of new opportunities. So far in 2026, first financings represented about 35% of deals but only about 22% of capital, which means follow-on companies captured most of the money.

The comparable 2025 period looked more favorable to new opportunities. First financings represented about 42% of deals and about 43% of capital over the comparable period in 2025, helped by large early clinical and therapeutics financings.

The full-year comparison also shows that 2025 was unusually open to new entrants. First financings rose from about 28% of 2024 deals to about 41% of 2025 deals, and their capital share rose from 18% to about 34%. That was a real new-company formation signal.

YTD 2026 has shifted back toward proven winners. Talkiatry, Grow Therapy, Big Health, Tava Health, InStride Health, Jimini Health, and Somethings all represent follow-on or scaled financing logic. The largest current checks favor companies with existing traction, payer fit, provider networks, clinical validation, or platform scale.

That does not mean new opportunities are closed out. New companies still raise large rounds when they bring clinical infrastructure, serious-disease specificity, regulated software, or drug-development depth. But the center of gravity has moved back toward validated companies.

Is the mental health market becoming winner-takes-most?

Yes, the mental health market is becoming winner-takes-most in capital allocation, though not in company formation. In 2025, the top 3 rounds captured about 60% of total capital, the top 10 captured about 88%, and the bottom half of deals captured only about 7%.

The 2024 comparison shows that concentration intensified. In 2024, the top 3 rounds captured about 36% of capital and the top 10 captured about 77%. The largest-deal-to-median-round ratio also jumped from about 7.1x in 2024 to about 29.8x in 2025.

YTD 2026 remains highly concentrated. The top 3 rounds captured about 58% of capital, the top 5 captured about 71%, and the top 10 captured about 89%. This is slightly less extreme than the comparable 2025 period, when the top 3 captured nearly 80%, but it is still a winner-takes-most funding pattern.

The important distinction is that many companies can still raise. Clinical Mental Health Apps produced 7 of 17 YTD 2026 deals, but captured only about 16% of capital. The market is broad in experimentation and narrow in dollar conviction.

The mental health market is therefore winner-takes-most for capital, not winner-takes-all for company formation. The biggest dollars go to a small group of companies that investors believe can become category infrastructure, scaled care networks, psychiatric capacity platforms, or serious clinical assets.

Is the next wave of mental health winners becoming visible?

Yes, the next wave of mental health winners is becoming visible, but the visible winners are not generic consumer mental health apps. The strongest emerging lanes are provider-network scale, psychiatry capacity, clinical AI infrastructure, serious mental illness care, FDA-cleared digital treatment, integrated clinics, and psychiatric therapeutics.

The YTD 2026 evidence is especially useful because the largest financings cluster around clear theses. Talkiatry and Grow Therapy signal continued investor belief in scaled mental health access and provider networks. Tava and InStride signal that specialty care delivery and insurance-linked therapy still matter.

Big Health signals that FDA-cleared digital therapeutics remain fundable when tied to adoption or reimbursement pathways. Salma and Radley signal renewed interest in higher-acuity clinic infrastructure. Ease, Oasys, Jimini, and Blossom signal that clinical operating systems and supervised AI infrastructure are becoming investable.

The full-year 2025 evidence adds another winner track: psychiatric medication services. MapLight, Syremis, Draig, and Newleos dominated 2025 capital, while Amani and Gilgamesh show that the neuropsychiatric therapeutics pipeline remains active in 2026.

The next winners are visible because they are absorbing meaningful institutional checks, not because they have fashionable positioning. The strongest companies can prove clinician leverage, payer fit, regulated clinical credibility, specialty acuity, or measurable care-delivery capacity. See the deeper analysis of the mental health market for the complete company-level view.

As this chart shows, and as featured in our mental health market deck, search interest in men’s mental health has been rising steadily

Is the mental health funding landscape fragmenting or consolidating?

The mental health funding landscape is consolidating by capital but fragmenting by company type. Capital is consolidating because the top rounds capture most of the money: the top 10 deals captured about 88% of capital in 2025 and about 89% so far in 2026.

At the same time, funded company types are fragmenting. The mental health market now includes therapy care providers, psychiatry care platforms, clinical mental health apps, psychiatric medication services, mental health clinics, and addiction treatment services. Within those categories, the funded models include school-based care, youth anxiety treatment, virtual psychiatry, AI operating systems, FDA-cleared digital therapeutics, serious mental illness clinics, peer support, interventional psychiatry, and neuropsychiatric drugs.

This combination matters. Fragmentation by model does not mean fragmentation by capital. Many models can attract some funding, but only a small number can attract large institutional rounds.

The cleanest example is Clinical Mental Health Apps. The category led YTD 2026 deal count with 7 deals, yet captured only about 16% of capital. The landscape is strategically broad, but the money is financially concentrated.

Where is investor attention shifting in the mental health market?

Investor attention in the mental health market is shifting toward clinical infrastructure, psychiatric capacity, payer-connected care delivery, and supervised or regulated technology. The category leadership rotation makes that clear: Therapy Care Providers led 2024 capital, Psychiatric Medication Services dominated 2025 capital, and YTD 2026 is led by Therapy Care Providers and Psychiatry Care Platforms together.

This rotation shows that investors are not rewarding one static mental health category. They are moving toward whichever model can best demonstrate clinical legitimacy, scalability, reimbursement fit, and defensibility in that period.

Investor attention is also moving away from generic wellness and toward higher-acuity or operationally embedded models. The strongest 2026 signals include Talkiatry for psychiatry access, Grow Therapy for provider networks, Salma for integrated brain-health clinics, Ease for behavioral-health operating systems, Big Health for FDA-cleared digital treatments, and InStride for specialty youth anxiety and OCD care.

Youth mental health is a real theme, but investors have not converged on one delivery format. Somethings uses peer support, InStride uses specialty clinical treatment, The Path uses AI-guided support with escalation, and school-linked platforms appear through behavioral-health infrastructure and care models.

The clearest reading is that investor attention has shifted from “mental health demand is huge” to “which model can deliver care at scale under clinical and reimbursement constraints.” For ongoing tracking of this shift, see the mental health market report.

This chart, featured in our mental health market deck, shows how therapy matchmaking platform technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.